Trial · NCT04663347
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
NCT04663347, Phase 1, Phase 2, Active not recruiting, Genmab
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL). Trials, record NCT04663347. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04663347
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
- NCT number
- NCT04663347
- Status
- Active not recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 543 participants, actual
- Lead sponsor
- Genmab
- Conditions
- Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
- Interventions
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, rituximab and lenalidomide, rituximab and bendamustine, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, gemcitabine and oxaliplatin, Epcoritamab, rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone, Lenalidomide, rituximab, ifosfamide, carboplatin, and etoposide phosphate, Epcoritamab, Epcoritamab, Epcoritamab, Epcoritamab, Epcoritamab, Epcoritamab, Epcoritamab, Rituximab and Lenalidomide, Epcoritamab
- First posted
- 2020-12-11
- Last updated
- 2026-11-03
- Other registries' IDs
- eudract:2020-000845-15
Source ClinicalTrials.gov
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1: Number of Participants With Dose limiting Toxicities (DLTs) | During the first cycle (Cycle length= 28 days) in each cohort | DLT events are defined as clinically significant adverse events (AEs) or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications as assessed per Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0. |
| Primary | Part 1 and Part 2 (Arms 1-5, 7 and 10): Number of Participants With Adverse Events (AEs) | From first dose of drug until either 60 days after last dose, date participant withdraws consent, date participant starts a new systemic anticancer therapy, or date participant dies, whichever occurs first (up to approximately 3 years) | An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign. (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. |
| Primary | Part 2 (Except Arm 7): Overall Response Rate (ORR) | Up to 3 years | ORR is defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on Lugano criteria. |
| Secondary | Part 1 and 2: Clearance (CL) of Epcoritamab | Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years) | |
| Secondary | Part 1 and 2: Area Under the Concentration-Time Curve (AUC) of Epcoritamab | Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years) | |
| Secondary | Part 1 and 2: Maximum (Peak) Plasma Concentration (Cmax) of Epcoritamab | Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years) | |
| Secondary | Part 1 and 2: Time to Reach Cmax (Tmax) of Epcoritamab | Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years) | |
| Secondary | Part 1 and 2: Terminal Elimination Half-Life (t 1/2) of Epcoritamab | Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years) | |
| Secondary | Part 1 and 2: Number of Immune Cell Populations | Up to 2 years | Immune cell populations in peripheral blood and tumor biopsies will be assessed. |
| Secondary | Part 1 and 2: Percentage of Immune Cell Populations | Up to 2 years | Immune cell populations in peripheral blood and tumor biopsies will be assessed. |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04663347
GET https://conductscience.org/api/trials/v1/NCT04663347/registered?page=2